{
  "id": "df5e5bdb87a4d200",
  "title": "Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non - Dilutive Funds from Closing of License Deal for Mytesi",
  "description": "20260122T180000Z",
  "content": "",
  "source": "tennesseedaily.com",
  "source_url": "http://www.tennesseedaily.com/news/278824279/jaguar-health-highlights-sharp-strategic-focus-on-rare-intestinal-failure-diseases-fueled-by-non-dilutive-funds-from-closing-of-license-deal-for-mytesi",
  "published_at": "20260122T180000Z",
  "fetched_at": "2026-01-23T00:24:24.269073+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.tennesseedaily.com/news/278824279/jaguar-health-highlights-sharp-strategic-focus-on-rare-intestinal-failure-diseases-fueled-by-non-dilutive-funds-from-closing-of-license-deal-for-mytesi",
    "url_mobile": "",
    "title": "Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non - Dilutive Funds from Closing of License Deal for Mytesi",
    "seendate": "20260122T180000Z",
    "socialimage": "",
    "domain": "tennesseedaily.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}